We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Department of Internal Medicine, Division of Infectious and Immunologic Diseases, University of California Davis Medical Center, Sacramento
Dale N. Gerding
Affiliation:
Research Service, Edward Hines Jr Veterans Administration Hospital, and the Infectious Disease Division, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois
Stuart Johnson
Affiliation:
Research Service, Edward Hines Jr Veterans Administration Hospital, and the Infectious Disease Division, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Drekonja, DM. Rifampin plus metronidazole for Clostridium difficile infection. Infect Control Hosp Epidemiol2010;31(11):1205 (in this issue).CrossRefGoogle ScholarPubMed
2
2.Lagrotteria, D, Holmes, S, Smieja, M, Smaili, F, Lee, C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis2006;43:547–552.CrossRefGoogle ScholarPubMed
3
3.Cohen, SH, Gerding, DN, Johnson, S, et al.Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol2010;31(11):431–455.Google Scholar